Brodalumab

Brodalumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Interleukin 17 receptor A
Clinical data
Trade names	Siliq, Kyntheum, Lumicef
Other names	KHK4827, AMG 827
License data	US DailyMed: Brodalumab;
ATC code	L04AC12 (WHO) ;
Legal status
Legal status	CA: ℞-only / Schedule D; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	1174395-19-7 ;
DrugBank	DB11776 ;
ChemSpider	none;
UNII	6ZA31Y954Z;
KEGG	D10061 ;
Chemical and physical data
Formula	C6372H9840N1712O1988S52
Molar mass	143905.93 g·mol−1
	(what is this?) (verify)

Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases.

In February 2017, it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.